Skip to main content
Terug
Watch Compare

Lexeo Therapeutics, Inc.

Datakwaliteit: 83%
LXEO
Nasdaq Manufacturing Chemicals
€ 5,98
▼ € 0,45 (-7,00%)
Marktkapitalisatie: 476,38 M
Prijs
€ 6,43
Marktkapitalisatie
476,38 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -98,96 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-77,18%
Onder sectorgemiddelde (-53,41%)
ROIC-63,69%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio7,40
Interest Coverage-1150,07

Waardering

PE (TTM)
-4,77
Onder sectorgemiddelde (-1,48)
P/B Ratio3,94
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -4,8 -1,5
P/B 3,9 1,6
ROE % -77,2 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BRSIX BRSIX
0,12% weight
JAGLX JAGLX
0,09% weight
JFNNX JFNNX
0,09% weight
JFNIX JFNIX
0,09% weight
JFNSX JFNSX
0,09% weight
JNGLX JNGLX
0,09% weight
JFNAX JFNAX
0,09% weight
JFNCX JFNCX
0,09% weight
GSCTX GSCTX
0,06% weight
GSATX GSATX
0,06% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -99,96 M
ROE -77,18% ROA -62,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -98,96 M
ROIC -63,69% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7,40
Interest Coverage -1150,07 Asset Turnover N/A
Working Capital 110,52 M Tangible Book Value 120,83 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,77 Forward P/E N/A
P/B Ratio 3,94 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -20,77%
Market Cap 476,38 M Enterprise Value 435,38 M
Per Share
EPS (Diluted TTM) -1,86 Revenue / Share N/A
FCF / Share -1,34 OCF / Share -1,33
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 99,00%
SBC-Adj. FCF -112,17 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue — — 654.000,0
Net Income -99,96 M -98,33 M -66,39 M
EPS (Diluted) -1,86 -3,09 -12,40
Gross Profit — — —
Operating Income -109,26 M -105,77 M -68,51 M
EBITDA — — —
R&D Expenses 63,80 M 74,09 M 53,13 M
SG&A Expenses — — —
D&A 268.000,0 304.000,0 271.000,0
Interest Expense 95.000,0 137.000,0 205.000,0
Income Tax 0,0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 268,69 M 146,94 M 139,81 M
Total Liabilities 22,02 M 30,10 M 26,27 M
Shareholders' Equity 246,67 M 116,84 M 113,54 M
Total Debt — — —
Cash & Equivalents 63,00 M 35,01 M 121,47 M
Current Assets 188,39 M 126,12 M 124,29 M
Current Liabilities 16,81 M 22,85 M 17,24 M